Names
Lynozyfic™ Linvoseltamab-gcptIndications and usage
Linvoseltamab-gcpt is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Side effects needing medical attention
The most common adverse reactions are musculoskeletal pain, cytokine release syndrome (CRS), cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and shortness of breath. The most common laboratory abnormalities are decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.